Brief: Inmune Bio Announces Approval Of Clinical Trial Application By U.K. Regulator For Phase 2 Clinical Trial In Alzheimer’s Disease
05/09/2023 14:08
Sept 5 (Reuters) - INmune Bio Inc INMB.O :
* INMUNE BIO INC. ANNOUNCES APPROVAL OF CLINICAL TRIAL
APPLICATION
BY THE U.K. MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY
FOR PHASE 2 CLINICAL TRIAL IN ALZHEIMER’S DISEASE
Source text for Eikon: ID:nGNX7r0c50
Further company coverage: INMB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inmune Bio
See all newsBrief: Inmune Bio - Enters Master Services Agreement With Uniphar For Ebstrocel International Commercialization
Brief: Inmune Bio Targets UK Maa In Q4 2026, EU Maa And US BLA In Q1 2027
INmune Bio Inc reports results for the quarter ended June 30 - Earnings Summary
INmune Bio Q2 net loss narrows on lower impairment charges
INmune Bio Inc expected to post a loss of 21 cents a share - Earnings Preview